Sanofi under fire over priority US access to COVID-19 vaccine

Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Sanofi under fire over priority US access to COVID-19 vaccine

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features